Accordingly, analysis of scRNA-Seq data10 revealed a downregulation of B2M in SCLC patients treated with anti-PD1 immunotherapy in combination with chemotherapy whereas B2M was maintained in patients treated with chemotherapy alone (Fig. 9g, h). This evidence concerns the gene B2M and small cell lung carcinoma.